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Abstract
Yohimbine is a prototypical alpha2-adrenergic receptor antagonist. Due to its relatively high 
selectivity, yohimbine is often used in experiments whose purpose is to examine the role of these 
receptors. For example, yohimbine has been employed at doses of 1–5 mg/kg to reinstate drug-
seeking behavior after extinction or to antagonize general anesthesia, an effects presumably being 
a consequence of blocking alpha2-adrenergic receptors. In this report we characterized dose-
dependent autonomic and behavioral effects of yohimbine and its interaction with an antagonist of 
5-HT1A receptors, WAY 100635. In low doses (0.5 – 2 mg/kg i.p.) yohimbine induced locomotor 
activation which was accompanied by a tachycardia and mild hypertension. Increasing the dose to 
3–4.5 mg/kg reversed the hypertension and locomotor activation and induced profound 
hypothermia. The hypothermia as well as the suppression of the locomotion and the hypertension 
could be reversed by the blockade of 5-HT1A receptors with WAY 100635. Our data confirm that 
yohimbine possesses 5-HT1A properties, and demonstrated that in doses above 1 mg/kg 
significantly activate these receptors.
1. INTRODUCTION
Yohimbine is a prototypical alpha-2 adrenoreceptor antagonist in neuropharmacological 
studies [16]. It was and still is widely used in various experimental studies in vitro [10, 19, 
34] and in vivo in conscious animals [3, 5, 7] and as an antagonist of general anesthesia [11, 
22, 24, 48].
Importantly, yohimbine has also been reported to evoke responses through dopaminergic 
[40], alpha1-adrenergic [13, 16], 5-HT1A [50, 51], and benzodiazepine [29] receptors. The 
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ability of yohimbine to act as a partial agonist for the human 5-HT1A receptor was 
demonstrated using receptors expressed in cell lines [1]. Hypothermia, induced by 
yohimbine in rats [21, 32] was linked to the activation of 5-HT1A receptors [32].
A major limitation of the above-referenced studies is that they do not provide data 
establishing the relative receptor selectivity of the doses of yohimbine employed in 
conscious animals. If yohimbine evokes some action in doses which are non-specific for 
alpha2-adrenoreceptors, then its pharmacological action needs to be interpreted with 
caution. For example, yohimbine–induced reinstatement of drug-seeking behavior is usually 
assumed to be alpha2-adrenoreceptor-mediated based on the widely known alpha2-blocking 
properties of the drug [2, 4]. However, alpha2-receptor antagonistRS-79948 did not trigger 
reinstatement despite it blocked effects of clonidine [46]. Also, in many studies yohimbine 
was used in high doses (1–5 mg/kg), which exceed those sufficient to block alpha2-
adrenoreceptors.
To determine the doses of yohimbine which significantly activate 5-HT1A receptors in 
conscious rats we studied dose-dependence of the effects of yohimbine and identified those 
mediated by 5-HT1A receptors by using WAY 100635, a specific antagonist of these 
receptors.
2. MATERIALS AND METHODS
2.1. Animal model
Male Sprague-Dawley rats (250–300 g) were used for all experiments. The animals were 
individually housed under standard controlled conditions (lights on 07:00–19:00, room 
temperature of 23–25°C) with free access to food and water. All procedures described were 
approved by the IACUC of the Indiana University School of Medicine and followed NIH 
guidelines.
Rats were implanted with telemetric transmitters (PXT, Transoma Med, St.Paul, MN) under 
isoflurane anesthesia as previously described [47]. After at least seven days of recovery, rats 
were brought to experimental room, placed on receivers of telemetric data acquisition 
system (LabPro 3.11, Data Sciences Int., St.Paul, MN) and allowed to adapt to experimental 
conditions. All animals for which data are reported remained in good health throughout the 
course of surgical procedures and experimental protocols as assessed by appearance, 
behavior, and maintenance of body weight.
2.2. Drugs
Yohimbine hydrochloride and WAY100635(WAY) were obtained from the Sigma-Aldrich 
(St. Louis, MO). WAY was dissolved in sterile saline. Yohimbine was first dissolved in an 
aliquot of distilled water under sonication, and then an equal volume of hypertonic saline 
(1.8% solution of NaCl in distilled water) was added.
2.3. Experimental Protocols
All injections were performed between 11:00 am and 2:00 pm to avoid the effect of 
circadian variability. Two experimental series were performed.
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In the first series of experiments, thermal, locomotor, and cardiovascular responses to 
various doses of yohimbine were studied. Five doses of yohimbine (0.5, 1, 2, 3, or 4.5 mg/kg 
in a volume of 1 ml/kg) or sterile saline were given i.p. Animals (N=4) received all doses of 
yohimbine in random order allowing two days between experiments.
In second series of experiments, three groups of rats (N=5 each) were prepared. Each rat was 
given two identical i.p. injections of either 0.5 or 3 mg/kg of yohimbine or vehicle separated 
by 2 days. Administration of yohimbine or saline was preceded by i.p. injection of either 
WAY (0.5 mg/kg in 1 ml/kg of saline) or saline. The selection of pretreatment for first trial 
was done by randomization. If in first trial the pretreatment was WAY, than pretreatment for 
the second trial was saline and vice versa.
2.4. Statistical analysis
The results are presented as the mean±SEM. For bar graphs and statistical comparisons we 
have averaged parameters between 15 and 30 min after injection of yohimbine, because this 
interval is close to maximal changes after both 0.5 and 3 mg/kg yohimbine. Baseline levels 
of activity, body temperature, heart rate (HR), and mean blood pressure (MBP) did not differ 
between groups across the series of experiments, so changes from baseline were analyzed 
unless specially noted.
Results were compared using a one way (series 1) or two-way (series 2) ANOVA with 
repeated measures followed by a Duncan post hoc test, where appropriate. A value of 
p<0.05 was considered to indicate a significant difference.
3. Results
Yohimbine dose-dependently affected all of the studied parameters: heart rate, blood 
pressure, body temperature, and locomotion (Fig. 1, locomotion F(5,18)=4.1; p=0.01; HR 
F(5,18)=7.8; p<0.001; MBP F(5,18)=5.9; p=0.002; temperature F(5,18)=21.5; p<0.001). In 
low doses (0.5 – 2 mg/kg i.p.) yohimbine induced locomotor activation accompanied by 
tachycardia, mild hypertension, and a trend to a hyperthermia (Fig. 1). In higher doses (3 
and 4.5 mg/kg) yohimbine reversed hypertension (Fig. 1C) and locomotor activation (Fig. 
1A) but not tachycardia (Fig. 1B). The trend to increasing body temperature visible after 0.5 
mg/kg was reversed by higher doses, and body temperature after 2 mg/kg was significantly 
lower than after 0.5 mg/kg, (Fig. 1D). In higher doses yohimbine induced dramatic 
hypothermia (Fig. 1D). Core body temperature fell to 34.7±0.6°C after 3 mg/kg yohimbine 
and to 33.4±0.9°C after 4.5 mg/kg yohimbine. The rates of decline in temperature between 5 
and 30 min were similar after 3 mg/kg and 4.5 mg/kg yohimbine (0.058±0.019°C/min vs 
0.058±0.004°C/min), but the nadir occurred later after the higher dose (59±14 min vs 
118±19 min). Dose-response curve for yohimbine for temperature had a clear sigmoidal 
shape with EC50 equal 2.2 mg/kg (95% confidence interval 1.8–2.6 mg/kg).
Pretreatment with WAY (0.5 mg/kg, i.p.) had effects on all parameters (locomotion 
F(1,12)=10.9; p<0.05; HR F(1,12)=50.4; p<0.001; MBP F(1,12)=19.0; p<0.001; 
temperature F(1,12)=64.7; p<0.001) and effect on temperature was also dependent on the 
dose of yohimbine (F(2,12)=18.0; p<0.001). Administration of WAY did not affect the 
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locomotor response to i.p. injection of saline or 0.5 mg/kg yohimbine, however it 
significantly increased locomotion after 3 mg/kg yohimbine (Fig. 2, A1–D1). 
Administration of WAY moderately increased (i.e., by approximately 50 beats/min) 
tachycardia seen in response to saline and both 0.5 and 3.0 mg/kg yohimbine (Fig 2, A2–
D2). Unlike heart rate, the effect of WAY on blood pressure changes induced by yohimbine 
was dependent on the dose of yohimbine (Fig. 2, A3–D3). Increase of blood pressure 
induced by 0.5 mg/kg yohimbine was modified not significantly by WAY, but pretreatment 
with the antagonist of 5-HT1A receptors clearly prevented a drop of blood pressure after 3 
mg/kg yohimbine (Fig. 2, C3–D3). Finally, the 5-HT1A antagonist slightly increased 
hyperthermic response to injections of saline or 0.5 mg/kg yohimbine (Fig. 2, A4–D4). 
However, administration of WAY completely abolished hypothermia evoked by 3 mg/kg 
yohimbine (Fig. 2, C4–D4).
4. Discussion
In many studies, in which yohimbine was used as a prototypical alpha2-adrenoblocker, 
doses of drug were significantly higher than required for specific effects of this compound 
on the alpha2-adrenoreceptor. Our data unequivocally demonstrated that high doses of 
yohimbine activate 5HT1A receptors.
Administration of yohimbine at high doses results in significant hypothermia, similar to 
decrease of body temperature evoked by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-
DPAT), a prototypical 5-HT1A agonist [17]. Yohimbine-induced hypothermia is prevented 
by WAY (our data and [32]) in a dose specific for 5-HT1A blocking action [18]. Previously, 
we demonstrated that hypothermia evoked by systemic administration of the 8-OH-DPAT is 
mediated by activation of 5-HT1A receptors in the ventromedial medulla [39]. Most likely, 
the effect of systemically-administered yohimbine on core body temperature is also 
mediated by the inhibition of ventromedial medulla through activation of 5-HT1A receptors: 
the rate of cooling after high dose of yohimbine (0.06±0.02°C/min after 3 mg/kg yohimbine) 
is similar to one induced by inhibition of neuronal activity in ventromedial medulla [52].
What is the dose of yohimbine which can be clearly identified as evoking 5-HT1A effect, 
using body temperature as an experimental end-point? Administration of 3 mg/kg results in 
clear hypothermia. Considering that the slope of temperature decline after 3 mg/kg is similar 
to the one after 4.5 mg/kg, the effect of yohimbine on thermoregulation is saturated at 3 
mg/kg. The administration of 2 mg/kg results in significantly lower body temperature 
compared with lowest studied dose (0.5 mg/kg). In fact, if there is a progressive increase of 
hyperthermic action with increasing dose, then hypothermic effect of 1 mg/kg would simply 
be masked. Non-linear regression of dose-dependency of the hypothermic effects of 
yohimbine results in EC50 estimate of 2.2 mg/kg. Therefore, we conclude that in doses 
above 1 mg/kg yohimbine has considerable 5-HT1A agonistic activity when administered 
intraperitoneally. This estimation is supported by complete suppression of serotonergic 
neurons in the dorsal raphe nucleus by 0.5 mg/kg yohimbine intravenously, which could be 
reversed by WAY [32].
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The data in the National Institute of Mental Health – Psychoactive Drug Screening Program 
(NIMH-PDSP) database reveal, that in rats yohimbine is approximately 80-fold more 
selective for alpha-2 adrenergic receptors than to 5HT1A receptors. This selectivity 
corresponds to the ratio of doses needed to activate 5-HT1A receptors to doses required to 
block alpha2-adrenoreceptors in conscious rats. Is it possible that WAY blocks hypothermic 
effects of yohimbine through receptors other than 5-HT1A ? WAY does not affect alpha1-
adrenoreceptor-mediated responses in doses below 1 mg/kg [49], and the sensitivity of 
alpha2-adrenoreceptors to WAY is at least twice less than that of alpha1-adrenoreceptors 
(PDSP database). According to PDSP database the only other candidate receptor, to which 
both substances could bind with reasonable affinity, is the D2 receptor. However, the 
reported threshold dose in which WAY blocks effects on 5-HT1A is 6 µg/kg [35], and the 
ratio of Ki for WAY acting on two receptors exceeds 1000 (0.24 nM for 5-HT1A vs 370 nM 
for D2, PDSP), than the dose in this study (0.5 mg/kg) is not sufficient to block effects on 
D2.
Presence of 5-HT1A-mediated effects of yohimbine in doses higher than 1 mg/kg can be 
found using other experimental end-points. Yohimbine-induced locomotion after 0.5 mg/kg 
was not affected by WAY, while the effect of 3 mg/kg was augmented by WAY. 
Considering that the administration of 8-OH-DPAT, an agonist of 5-HT1A receptors, 
increases locomotion by itself [12, 14], but suppresses locomotion induced by other stimuli 
[8, 20], this double action can explain the relatively small locomotor responses to yohimbine 
[42] and its ability to suppress locomotion in behavioral paradigms [9].
In low doses yohimbine increased inferior cardiac nerve discharge [30] and caused 
tachycardia [25, 38]. However, in higher doses yohimbine inhibited nerve discharge, and 
this inhibition was reversed by spiperone [30], an agent with 5-HT1A-antagonist properties 
[28]. Similarly, we found that high dose of yohimbine caused the reversal of hypertonic 
response, and this reversal was completely prevented by pretreatment with WAY. 
Yohimbine has also other effects typical for 5-HT1A agonists, such as release of ACTH and 
corticosterone [36], which was observed in rats only in doses higher than 1 mg/kg [45].
There are accumulating data on the importance of 5-HT1A agonistic properties of 
yohimbine in experimental studies. Yohimbine (2.5–7.5 mg/kg) disrupted prepulse 
inhibition [37] and produced antinociception [43] in rats via the action at 5-HT1A receptors 
but not at alpha2-adrenoceptors. Ability of alpha2-adrenoblockers to affect 5-HT1A 
receptors is not unique for yohimbine: BRL-44408 recognizes 5-HT1A receptors along with 
being alpha2-adrenoceptor antagonist [31].
Understanding dose-dependence of effects of yohimbine mediated by different receptors has 
a potential to affect interpretation of various phenomena related to the use of this drug. 
Yohimbine is known to reinstate methamphetamine [44], cocaine [15, 27], and alcohol 
seeking [26] behaviors, and it is assumed that these actions result from a blockade of alpha2-
adrenoceptors [4, 26]. However, the doses of yohimbine in all these studies (1.25–5 mg/kg) 
appear to be sufficient to activate 5-HT1A receptors, while a dose less than 1 mg/kg was not 
effective in reinstating food-seeking behavior [33]. Considering that yohimbine is quickly 
accumulated in the brain but is eliminated with t1/2 of 7.7 h [23], the need to use high doses 
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cannot be justified by pharmacokinetics. A potential role of 5-HT1A receptors is supported 
by the ability of WAY to attenuate cocaine-induced reinstatement [6, 41].
Similarly, an antagonism of general anesthesia in rats also requires 1–2 mg/kg of yohimbine 
[22], while 0.25 mg/kg of yohimbine did not reverse the anesthesia in cats [48]. We 
conclude that in the doses, in which it is used in many experimental paradigms, yohimbine is 
also a 5-HT1A agonist.
Acknowledgements
Research reported in this publication was supported by the NIH under award numbers NS19883, MH65697, 
DA026867, and was conducted in a facility constructed under support from the National Center for Research 
Resources of the NIH under award number C06 RR015481-010. Pamela Durant is gratefully acknowledged for 
editorial assistance.
REFERENCES
1. Arthur JM, Casañas SJ, Raymond JR. Partial agonist properties of rauwolscine and yohimbine for 
the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem Pharmacol. 
1993; 45:2337–2341. [PubMed: 8517875] 
2. Bertholomey ML, Verplaetse TL, Czachowski CL. Alterations in ethanol seeking and self-
administration following yohimbine in selectively bred alcohol-preferring (P) and high alcohol 
drinking (HAD-2) rats. Behav Brain Res. 2013; 238:252–258. [PubMed: 23103404] 
3. Bhalla S, Rapolaviciute V, Gulati A. Determination of α(2)-adrenoceptor and imidazoline receptor 
involvement in augmentation of morphine and oxycodone analgesia by agmatine and BMS182874. 
Eur J Pharmacol. 2011; 651:109–121. [PubMed: 21114998] 
4. Bossert JM, Marchant NJ, Calu DJ, Shaham Y. The reinstatement model of drug relapse: recent 
neurobiological findings, emerging research topics, and translational research. 
Psychopharmacology. 2013; 229:453–476. [PubMed: 23685858] 
5. Branch CA, Knuepfer MM. Adrenergic mechanisms underlying cardiac and vascular responses to 
cocaine in conscious rats. The Journal of pharmacology and experimental therapeutics. 1992; 
263:742–751. [PubMed: 1359113] 
6. Burmeister JJ, Lungren EM, Kirschner KF, Neisewander JL. Differential roles of 5-HT receptor 
subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology. 2004; 29:660–668. [PubMed: 14627998] 
7. Cai JJ, Morgan DA, Haynes WG, Martins JB, Lee HC. Alpha 2-Adrenergic stimulation is protective 
against ischemia-reperfusion-induced ventricular arrhythmias in vivo. American journal of 
physiology. Heart and circulatory physiology. 2002; 283:H2606–H2611. [PubMed: 12427600] 
8. Carey RJ, Shanahan A, Damianopoulos EN, Müller CP, Huston JP. Behavior selectively elicited by 
novel stimuli: modulation by the 5-HT1A agonist 8-OHDPAT and antagonist WAY-100635. Behav 
Pharmacol. 2008; 19:361–364. [PubMed: 18622186] 
9. Chopin P, Pellow S, File SE. The effects of yohimbine on exploratory and locomotor behaviour are 
attributable to its effects at noradrenaline and not at benzodiazepine receptors. Neuropharmacology. 
1986; 25:53–57. [PubMed: 2869438] 
10. Cleary L, Vandeputte C, Docherty JR. Investigation of postjunctional alpha1- and alpha2-
adrenoceptor subtypes in vas deferens from wild-type and alpha(2A/D)-adrenoceptor knockout 
mice. Br J Pharmacol. 2003; 138:1069–1076. [PubMed: 12684262] 
11. Degernes LA, Kreeger TJ, Mandsager R, Redig PT. Ketamine-xylazine anesthesia in red-tailed 
hawks with antagonism by yohimbine. J Wildl Dis. 1988; 24:322–326. [PubMed: 3373637] 
12. Dourish CT, Hutson PH, Curzon G. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-
n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology. 1985; 
86:197–204. [PubMed: 3161115] 
Zaretsky et al. Page 6









13. Doxey JC, Lane AC, Roach AG, Virdee NK. Comparison of the alpha-adrenoceptor antagonist 
profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn 
Schmiedebergs Arch Pharmacol. 1984; 325:136–144. [PubMed: 6144048] 
14. Evenden JL, Angeby-Möller K. Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) 
on locomotor activity and rearing of mice and rats. Psychopharmacology. 1990; 102:485–491. 
[PubMed: 2151401] 
15. Feltenstein MW, See RE. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by 
the anxiogenic drug yohimbine. Behav Brain Res. 2006; 174:1–8. [PubMed: 16920204] 
16. Goldberg MR, Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-
adrenoreceptor. Pharmacol Rev. 1983; 35:143–180. [PubMed: 6140686] 
17. Goodwin GM, Green AR. A behavioural and biochemical study in mice and rats of putative 
selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1985; 84:743–
753. [PubMed: 2580582] 
18. Griebel G, Rodgers RJ, Perrault G, Sanger DJ. The effects of compounds varying in selectivity as 
5-HT(1A) receptor antagonists in three rat models of anxiety. Neuropharmacology. 2000; 
39:1848–1857. [PubMed: 10884565] 
19. Hikasa Y, Masuda K, Asakura Y, Yamashita Y, Sato C, Kamio M, Miura A, Taniguchi T, 
Minamizuru N. Identification and characterization of platelet α2-adrenoceptors and imidazoline 
receptors in rats, rabbits, cats, dogs, cattle, and horses. Eur J Pharmacol. 2013; 720:363–375. 
[PubMed: 24120658] 
20. Hillegaart V, Wadenberg ML, Ahlenius S. Effects of 8-OH-DPAT on motor activity in the rat. 
Pharmacology, biochemistry, and behavior. 1989; 32:797–800.
21. Houtepen LC, Peterse DP, Westphal KG, Olivier B, Vinkers CH. The autonomic stress-induced 
hyperthermia response is not enhanced by several anxiogenic drugs. Physiol Behav. 2011; 
102:105–109. [PubMed: 20828578] 
22. Hsu WH, Bellin SI, Dellmann HD, Hanson CE. Xylazine-ketamine-induced anesthesia in rats and 
its antagonism by yohimbine. J Am Vet Med Assoc. 1986; 189:1040–1043. [PubMed: 3505923] 
23. Hubbard JW, Pfister SL, Biediger AM, Herzig TC, Keeton TK. The pharmacokinetic properties of 
yohimbine in the conscious rat. Naunyn Schmiedebergs Arch Pharmacol. 1988; 337:583–587. 
[PubMed: 3412496] 
24. Kreeger TJ, Seal US. Immobilization of coyotes with xylazine hydrochloride-ketamine 
hydrochloride and antagonism by yohimbine hydrochloride. J Wildl Dis. 1986; 22:604–606. 
[PubMed: 3503155] 
25. Lang WJ, Lambert GA, Rush ML. The role of the central nervous system in the cardiovascular 
responses to yohimbine. Arch Int Pharmacodyn Ther. 1975; 217:57–67. [PubMed: 242288] 
26. Lê AD, Harding S, Juzytsch W, Funk D, Shaham Y. Role of alpha-2 adrenoceptors in stress-
induced reinstatement of alcohol seeking and alcohol self-administration in rats. 
Psychopharmacology. 2005; 179:366–373. [PubMed: 15551068] 
27. Lee B, Tiefenbacher S, Platt DM, Spealman RD. Pharmacological blockade of alpha2-
adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology. 2004; 29:686–693. [PubMed: 14872205] 
28. Lum JT, Piercey MF. Electrophysiological evidence that spiperone is an antagonist of 5-HT1A 
receptors in the dorsal raphe nucleus. Eur J Pharmacol. 1988; 149:9–15. [PubMed: 2969339] 
29. Matsunaga T, Tsukada H, Nishiyama S, Sekine Y, Kakiuchi T, Iyo M, Mori N. Yohimbine 
increases the binding potential for [11C]flumazenil in the monkey brain. J Neural Transm. 2001; 
108:1375–1382. [PubMed: 11810402] 
30. McCall RB, Harris LT, King KA. Sympatholytic action of yohimbine mediated by 5-HT1A 
receptors. Eur J Pharmacol. 1991; 199:263–265. [PubMed: 1683291] 
31. Meana JJ, Callado LF, Pazos A, Grijalba B, García-Sevilla JA. The subtype-selective alpha 2-
adrenoceptor antagonists BRL 44408 and ARC 239 also recognize 5-HT1A receptors in the rat 
brain. Eur J Pharmacol. 1996; 312:385–388. [PubMed: 8894622] 
32. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, 
Boutin JA, Rivet JM, Dekeyne A, Gobert A. Agonist and antagonist actions of yohimbine as 
Zaretsky et al. Page 7









compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B) 
5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of 
frontocortical monoaminergic transmission and depressive states. Synapse. 2000; 35:79–95. 
[PubMed: 10611634] 
33. Nair SG, Gray SM, Ghitza UE. Role of food type in yohimbine- and pellet-priming-induced 
reinstatement of food seeking. Physiol Behav. 2006; 88:559–566. [PubMed: 16806322] 
34. Nord EP, Howard MJ, Hafezi A, Moradeshagi P, Vaystub S, Insel PA. Alpha 2 adrenergic agonists 
stimulate Na+-H+ antiport activity in the rabbit renal proximal tubule. J Clin Invest. 1987; 
80:1755–1762. [PubMed: 2890661] 
35. O'Neill MF, Sanger GJ. GR46611 potentiates 5-HT1A receptor-mediated locomotor activity in the 
guinea pig. Eur J Pharmacol. 1999; 370:85–92. [PubMed: 10323255] 
36. Osei-Owusu P, James A, Crane J, Scrogin KE. 5-Hydroxytryptamine 1A receptors in the 
paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone 
release and some behavioral components of the serotonin syndrome. The Journal of pharmacology 
and experimental therapeutics. 2005; 313:1324–1330. [PubMed: 15743927] 
37. Powell SB, Palomo J, Carasso BS, Bakshi VP, Geyer MA. Yohimbine disrupts prepulse inhibition 
in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors. Psychopharmacology. 2005; 
180:491–500. [PubMed: 15719216] 
38. Rahman AR, Sharabi FM. Presynaptic alpha receptors in relation to the cardiovascular effect of 
yohimbine in the anesthetized cat. Arch Int Pharmacodyn Ther. 1981; 252:229–240. [PubMed: 
6118106] 
39. Rusyniak DE, Zaretskaia MV, Zaretsky DV, DiMicco JA. 3,4-Methylenedioxymethamphetamine- 
and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: role and location of 5-
hydroxytryptamine 1A receptors. The Journal of pharmacology and experimental therapeutics. 
2007; 323:477–487. [PubMed: 17702902] 
40. Scatton B, Zivkovic B, Dedek J. Antidopaminergic properties of yohimbine. The Journal of 
pharmacology and experimental therapeutics. 1980; 215:494–499. [PubMed: 7192314] 
41. Schenk S. Effects of the serotonin 5-HT(2) antagonist, ritanserin, and the serotonin 5-HT(1A) 
antagonist, WAY 100635, on cocaine-seeking in rats. Pharmacology, biochemistry, and behavior. 
2000; 67:363–369.
42. Schroeder BE, Schiltz CA, Kelley AE. Neural activation profile elicited by cues associated with 
the anxiogenic drug yohimbine differs from that observed for reward-paired cues. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology. 2003; 28:14–21. [PubMed: 12496936] 
43. Shannon HE, Lutz EA. Yohimbine produces antinociception in the formalin test in rats: 
involvement of serotonin(1A) receptors. Psychopharmacology. 2000; 149:93–97. [PubMed: 
10789888] 
44. Shepard JD, Bossert JM, Liu SY, Shaham Y. The anxiogenic drug yohimbine reinstates 
methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry. 2004; 55:1082–1089. 
[PubMed: 15158427] 
45. Shimizu K. Effect of alpha 1- and alpha 2-adrenoceptor agonists and antagonists on ACTH 
secretion in intact and in hypothalamic deafferentated rats. Jpn J Pharmacol. 1984; 36:23–33. 
[PubMed: 6150132] 
46. Smith RJ, Aston-Jones G. alpha(2) Adrenergic and imidazoline receptor agonists prevent cue-
induced cocaine seeking. Biol Psychiatry. 2011; 70:712–719. [PubMed: 21783176] 
47. Stotz-Potter EH, Morin SM, DiMicco JA. Effect of microinjection of muscimol into the 
dorsomedial or paraventricular hypothalamic nucleus on air stress-induced neuroendocrine and 
cardiovascular changes in rats. Brain Res. 1996; 742:219–224. [PubMed: 9117398] 
48. Verstegen J, Fargetton X, Zanker S, Donnay I, Ectors F. Antagonistic activities of atipamezole, 4-
aminopyridine and yohimbine against medetomidine/ketamine-induced anaesthesia in cats. Vet 
Rec. 1991; 128:57–60. [PubMed: 2003354] 
49. Villalobos-Molina R, Lopez-Guerrero JJ, Gallardo-Ortiz IA, Ibarra M. Evidence that the 
hypotensive effect of WAY 100635, a 5-HT1A receptor antagonist, is related to vascular alpha 1-
Zaretsky et al. Page 8









adrenoceptor blockade in the adult rat. Autonomic & autacoid pharmacology. 2002; 22:171–176. 
[PubMed: 12452902] 
50. Winter JC, Rabin RA. Antagonism of the stimulus effects of yohimbine and 8-
hydroxydipropylaminotetralin. Pharmacology, biochemistry, and behavior. 1993; 44:851–855.
51. Winter JC, Rabin RA. Yohimbine as a serotonergic agent: evidence from receptor binding and 
drug discrimination. The Journal of pharmacology and experimental therapeutics. 1992; 263:682–
689. [PubMed: 1359109] 
52. Zaretsky DV, Zaretskaia MV, DiMicco JA. Stimulation and blockade of GABA(A) receptors in the 
raphe pallidus: effects on body temperature, heart rate, and blood pressure in conscious rats. 
American journal of physiology. Regulatory, integrative and comparative physiology. 2003; 
285:R110–R116.
Zaretsky et al. Page 9










• Alpha2-adrenoblocking properties of yohimbine are observed in doses below 1 
mg/kg.
• In doses exceeding 1 mg/kg yohimbine is a 5-HT1A-agonist.
• Yohimbine reinstates drug-seeking behavior or antagonizes general anesthesia 
in high doses (more than 1 mg/kg).
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Physiological responses to intraperitoneal injection of saline or various doses of yohimbine. 
The data are averages of locomotor activity (A), heart rate (B), mean blood pressure (C) and 
body temperature (D) over interval of 15–30 minutes after injection. * - significant 
difference from saline (p<0.05). # - significant difference from the lowest dose (0.5 mg/kg, 
p<0.05).
Zaretsky et al. Page 11










Physiological responses to intraperitoneal injection of saline or WAY (0.5 mg/kg, i.p.) at 
time 0 followed by i.p. injection of saline or yohimbine (0.5 mg/kg or 3 mg/kg) at 5 min. 
The bar graphs (right column) show the averages of locomotor activity, cardiovascular 
parameters and core body temperature during the interval of 15–30 min after injection of 
yohimbine.
* - significant difference from saline pretreatment (p<0.05).
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